NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

Even with a COVID-19-related lull in the first half of 2020, investors’ appetite for new biotech listings on NASDAQ far surpassed demand in recent years, leading to a record-setting year for IPOs.

According to BioCentury’s BCIQ database, 65 biotechs raised a total of $12.8 billion in IPOs — more than twice the $5.8 billion raised in 2018, the most in any year prior. The analysis includes biopharmas that raised at least $50 million, and excludes diagnostics developers and service providers...